Figure 1
From: A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer
Maximum change from baseline in tumour burden in the evaluable population ( n =18): the mark (*) indicates the sensitive relapse group regarding the first-line chemotherapy.
